Profile data is unavailable for this security.
About the company
Jiangsu Kanion Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company provides capsules, oral liquid, granules, electuary, tablets, pills, patch and injections. The Company's products are applied in gynecology, orthopedics, cardiovascular and cerebrovascular, anti-infective, anti-tumor and others. The Company distributes its products mainly within domestic markets.
- Revenue in CNY (TTM)4.48bn
- Net income in CNY544.35m
- Incorporated2000
- Employees5.44k
- LocationJiangsu Kanion Pharmaceutical Co LtdJiangning Industrial ParkEconomic & Technological Development ZneLIANYUNGANG 222047ChinaCHN
- Phone+86 51 885521990
- Fax+86 51 885521990
- Websitehttps://www.kanion.com/
More ▼
Mergers & acquisitions
| Acquired company | 600557:SHH since announced | Transaction value |
|---|---|---|
| Jiangsu Xintrum Pharmaceuticals Co Ltd | -5.80% | 37.81m |
Data delayed at least 15 minutes, as of Nov 22 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Lukang Pharmaceutical Co Ltd | 6.08bn | 400.68m | 8.03bn | 6.48k | 20.18 | 2.06 | -- | 1.32 | 0.443 | 0.443 | 6.83 | 4.33 | 0.6850 | 3.39 | 6.92 | 937,972.80 | 4.66 | 2.21 | 7.60 | 4.05 | 22.74 | 23.41 | 6.80 | 3.46 | 0.8266 | 4.48 | 0.4744 | 31.79 | 9.34 | 13.04 | 78.37 | 8.81 | -16.95 | 23.94 |
| Shanghai Haoyuan Chemexpress Co Ltd | 2.12bn | 152.63m | 8.20bn | 3.37k | 53.71 | 3.03 | -- | 3.86 | 0.7235 | 0.7235 | 10.06 | 12.84 | 0.4823 | 1.00 | 3.71 | 629,969.20 | 3.42 | 7.38 | 4.66 | 9.60 | 44.42 | 47.03 | 7.08 | 13.53 | 1.01 | 4.45 | 0.3229 | 14.37 | 38.44 | 44.33 | -34.18 | 47.24 | 48.95 | -- |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 4.48bn | 544.35m | 8.65bn | 5.44k | 15.93 | 1.68 | -- | 1.93 | 0.9337 | 0.9337 | 7.69 | 8.85 | 0.6591 | 2.65 | 6.83 | 823,316.50 | 8.11 | 6.68 | 10.64 | 9.49 | 73.12 | 74.02 | 12.30 | 10.28 | 2.22 | -- | 0.00 | 25.57 | 11.88 | 4.94 | 23.54 | 5.33 | -1.87 | 35.99 |
| Aurisco Pharmaceutical Co Ltd | 1.43bn | 340.67m | 8.90bn | 1.52k | 26.96 | 3.92 | -- | 6.23 | 0.8124 | 0.8124 | 3.40 | 5.58 | 0.4716 | 1.14 | 4.72 | 939,069.60 | 11.23 | 12.40 | 13.35 | 14.33 | 57.16 | 51.26 | 23.81 | 23.05 | 2.82 | -- | 0.3049 | 25.15 | 25.24 | 17.02 | 37.23 | 16.16 | 26.54 | -- |
| Shanghai Yizhong Pharmaceutical Co Ltd | 250.66m | 65.60m | 8.91bn | 43.00 | 136.86 | 6.17 | -- | 35.54 | 0.3163 | 0.3163 | 1.21 | 7.02 | 0.1669 | 0.5372 | 2.00 | 5,829,320.00 | 4.37 | -0.9181 | 4.57 | -0.9485 | 94.00 | 93.19 | 26.17 | -6.11 | 17.37 | -- | 0.0075 | -- | 52.68 | -- | 13.09 | -- | 20.44 | -- |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.86bn | -24.94m | 9.18bn | 2.89k | -- | 1.41 | -- | 3.21 | -0.0074 | -0.0074 | 0.8379 | 1.89 | 0.2476 | 2.17 | 4.52 | 990,180.10 | -0.3138 | 2.26 | -0.4836 | 3.38 | 42.33 | 72.05 | -1.27 | 7.27 | 2.39 | -- | 0.1767 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
Data as of Nov 22 2024. Currency figures normalised to Jiangsu Kanion Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
12.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Investment Corp. (Investment Management)as of 06 Feb 2024 | 17.89m | 3.10% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 16.38m | 2.84% |
| China Southern Asset Management Co., Ltd.as of 06 Feb 2024 | 11.82m | 2.05% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 6.72m | 1.17% |
| Da Cheng Fund Management Co., Ltd.as of 06 Feb 2024 | 5.29m | 0.92% |
| Rongtong Fund Management Co., Ltd.as of 30 Sep 2023 | 5.00m | 0.87% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 2.80m | 0.49% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.58m | 0.27% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2024 | 1.57m | 0.27% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 1.53m | 0.27% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
